EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-Metaanalyse

Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis

Kunming Pan iD, Ranyi Li, Yanli Li, Xiaoqiang Ding, Xiaoyu Li, Qianzhou Lv

Journal of Antimicrobial Chemotherapy · 03.01.2025 · 80 (1) · 47-58

DOI: 10.1093/jac/dkae410 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 13.11.2024. Verfasst von Kunming Pan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Zhongshan Hospital FuDan University, 180 Fenglin Road, Shanghai, China. Hauptthemen laut MEDLINE: Vancomycin, Acute Kidney Injury, Piperacillin, Tazobactam Drug Combination, Anti-Bacterial Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 99 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China International Medical Foundation, Chinese Pharmaceutical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore whether vancomycin plus piperacillin/tazobactam actually increases nephrotoxicity compared with other anti-pseudomonal beta-lactams (BLs).

Methods

PubMed, Embase, Web of Science, Cochrane, CNKI, Wanfang and VIP were searched from inception to October 2023. The primary outcomes were acute kidney injury (AKI) as defined as acute increase in serum creatinine of 0.3 mg/dL or 50% and severe Stage 2–3 AKI.

Results

We included 70 studies (76 638 patients). Network meta-analysis indicated that vancomycin plus piperacillin/tazobactam was associated with significantly higher AKI risk than vancomycin plus cefepime (OR 2.55, 95% CI 2–3.28), vancomycin plus meropenem (OR 2.26, 95% CI 1.71–3.02) and vancomycin plus other uncommonly used BLs (OR 2.47, 95% CI 1.87–3.29). Also, vancomycin + piperacillin/tazobactam was associated with significantly higher Stage 2–3 AKI risk than vancomycin + cefepime (OR 2.22, 95% CI 1.34–3.62), vancomycin + meropenem (OR1.96, 95% CI 1.22–3.25) and vancomycin + uncommonly used BLs (OR 2.81, 95% CI 1.66–4.91). Vancomycin plus piperacillin/tazobactam did not result in a significant difference in the incidence of receiving dialysis treatment, mortality, length of stay and time to AKI. Subgroup analyses of studies conducting propensity score matching demonstrated vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates than vancomycin + cefepime (OR 2.19, 95% CI 1.38–3.47) and vancomycin + meropenem (OR 1.38, 95% CI. 1.18–1.60). Subgroup analysis of critically ill patients and children indicated that vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates.

Conclusions

Vancomycin + piperacillin/tazobactam significantly increased the risk of AKI and severe Stage 2–3 AKI compared with vancomycin plus other BLs. More prospective studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinAcute Kidney InjuryPiperacillin, Tazobactam Drug CombinationAnti-Bacterial AgentsDrug Therapy, CombinationHumansbeta-LactamsCefepimeMeropenem

Substanzen

VancomycinPiperacillin, Tazobactam Drug CombinationAnti-Bacterial Agentsbeta-LactamsCefepimeMeropenem

Autor:innen und Institutionen

  • Department of Pharmacy, Zhongshan Hospital FuDan University, 180 Fenglin Road, Shanghai, China.
  • Department of Nephropathy, Zhongshan Hospital FuDan University, 180 Fenglin Road, Shanghai, China.

ORCID-Profile: Kunming Pan

Förderung

  • National Natural Science Foundation of China
  • China International Medical Foundation
  • Chinese Pharmaceutical Association
  • Shanghai Pharmaceutical Association
  • Shanghai Municipal Health Commission
  • Shanghai Hospital Development Center Foundation

Zitieren

APA

Pan, K., Li, R., Li, Y., Ding, X., Li, X., & Lv, Q. (2025). Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis. Journal of Antimicrobial Chemotherapy, 80(1), 47-58. https://doi.org/10.1093/jac/dkae410

Vancouver

Pan K, Li R, Li Y, Ding X, Li X, Lv Q. Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis. Journal of Antimicrobial Chemotherapy. 2025;80(1):47-58. doi:10.1093/jac/dkae410

BibTeX
@article{Pan2025,
  author = {Pan, Kunming and Li, Ranyi and Li, Yanli and Ding, Xiaoqiang and Li, Xiaoyu and Lv, Qianzhou},
  title = {Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {1},
  pages = {47--58},
  doi = {10.1093/jac/dkae410}
}
Kostenlos starten →